Replies to post #203311 on Biotech Values

[biomaven0]

>>is the pk of the drug so tricky?

Once it binds to the target it gets rapidly degraded - so called "target mediated drug disposition." That's pretty unusual and likely inherent in this target.

Most proteins that are present at low concentration are that way because they are both made slowly and also degraded slowly. CTGF seems to be different - it seems to be both made and then degraded fairly rapidly.

http://link.springer.com/article/10.1007%2Fs11095-016-1918-0

In practical terms, if someone is making abnormally large amounts on a continuing basis, then you will have to dose that person at higher levels (or more frequently) to get the same free drug levels.

Now maybe the higher doses they now use have taken care of the issue - I just don't know. Or it might be that for some patients you have to individualize the dose.